The role of hatcheries, hatching eggs and one day old chicks in dissemination of beta lactam antibiotic resistance Pseudomonas aeruginosa (ESBL)

ABSTRACT The increasing incidence of infections caused by multidrug-resistant Pseudomonas aeruginosa is a worldwide health problem. Because no new antipseudomonal agents are expected to be available in the near future, we evaluated the safety and efficacy of colistin, an old drug with bactericidal activity against this organism. We collected clinical and demographic data on 95 cancer patients diagnosed with infections caused by multidrug-resistant P. aeruginosa between January 2001 and January 2004 and treated with either colistin (colistin group) or at least one active antipseudomonal agent (a beta-lactam antibiotic or a quinolone) (control group). We compared the results obtained for both groups. Thirty-one patients had been treated with colistin and 64 had been treated with an antipseudomonal non-colistin-containing regimen. Compared with the control group, patients in the colistin group had a lower median age (52 and 62 years, respectively; P = 0.012) but were more likely to have had nosocomial infections (87% and 64%, respectively; P = 0.02). Twenty-five patients (81%) in the colistin group and 40 patients (63%) in the control group had an APACHE II score of >15 (P = 0.074). The overall clinical response rates were 52% in the colistin group and 31% in the control group (P = 0.055). Multiple logistic regression analysis showed that those patients treated with colistin were 2.9 times (95% confidence interval, 1.1 to 7.6 times) more likely than those in the control group to experience a clinical response to therapy (P = 0.026). Colistin therapy was at least as effective and as safe a beta-lactam antibiotic or a quinolone in the treatment of infections caused by multidrug-resistant P. aeruginosa and, hence, may be a useful or preferred alternative therapy for this infection in cancer patients.

Download Full-text

Zinc Finger Nuclease: A New Approach to Overcome Beta-Lactam Antibiotic Resistance

Jundishapur Journal of Microbiology ◽

10.5812/jjm.29384 ◽

2016 ◽

Vol 9 (1) ◽

Cited By ~ 6

Author(s):

Mansoureh Shahbazi Dastjerdeh ◽

Shirin Kouhpayeh ◽

Faezeh Sabzehei ◽

Hossein Khanahmad ◽

Mansour Salehi ◽

...

Keyword(s):

Antibiotic Resistance ◽

Zinc Finger ◽

Zinc Finger Nuclease ◽

Beta Lactam ◽

New Approach ◽

Beta Lactam Antibiotic ◽

Lactam Antibiotic

Download Full-text

Limited contribution of the outer-membrane penetration barrier towards intrinsic antibiotic resistance in Pseudomonas aeruginosa

Canadian Journal of Microbiology ◽

10.1139/m82-022 ◽

1982 ◽

Vol 28 (2) ◽

pp. 169-175 ◽

Cited By ~ 5

Author(s):

R. Allan Scudamore ◽

Morris Goldner

Keyword(s):

Pseudomonas Aeruginosa ◽

Antibiotic Resistance ◽

Outer Membrane ◽

Cell Envelope ◽

Growth Curves ◽

Beta Lactam ◽

Intrinsic Resistance ◽

Beta Lactam Antibiotics ◽

High Level

The role of the outer membrane (OM) was investigated in relation to the high level of intrinsic antibiotic resistance of Pseudomonas aeruginosa ATCC 9027. OM penetration barriers were measured by comparing turbidimetric growth curves of EDTA-treated and normal cells exposed to carbenicillin, moxalactam (LY 127935), gentamicin, tobramycin, rifampin, novobiocin, and vancomycin. OM barriers were also measured for carbenicillin and moxalactam in P. aeruginosa strain K 799/61, a hypersusceptible mutant presumed to have lost its penetration barrier in the cell envelope. Most antibiotics penetrated the OM efficiently and there was little difference between the two strains. The evidence therefore suggests that intrinsic resistance of P. aeruginosa, especially to the beta-lactam antibiotics, is not mainly due to the OM. A penetration barrier situated deeper within the cell envelope is hypothesized, the size of which in relation to any antibiotic may be estimated by comparing the IC50 values of EDTA-treated cells of the two strains.

Download Full-text